Amyan Aalkhalegy
Research Subjects
Amyan Aalkhalegy has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Alreem Al-Naimi
1 shared publication- Amal Mahmoud Mohamed
National Research Centre
1 shared publication Haya Salem
1 shared publication- Ingy Badawy
Faculty of Biotechnology, Misr University for Science and Technology (MUST), 6 October City, Giza Egypt
1 shared publication - Lamiaa Abdelfattah Fathalla
Clinical Pathology,National Cancer Institute, Cairo University, Cairo Egypt
1 shared publication Lolwa Alansari
1 shared publication
Latest Publications
- 25 November 2022
- Published by Elsevier in Endocrine Practice
- Vol. 28 (12) , S54-S55
Abstract #1316108: The Role of Anti-Mullerian Hormone and Other Correlates in Polycystic Ovary Syndrome Patients
- 25 November 2022
- Published by Elsevier in Endocrine Practice
- Vol. 28 (12) , S54-S55
Abstract #1316108: The Role of Anti-Mullerian Hormone and Other Correlates in Polycystic Ovary Syndrome Patients
- 3 November 2020
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 16, 1-8
Role of MicroRNAs (224 and 96) as Novel Biomarkers for Hepatocellular Carcinoma
Background:: In the early stages of HCC, it is unsatisfactory to depend on alpha-fetoprotein for diagnosis. Objective:: The current study evaluated the possibility of the two miRNAs which are miRNA-96 and miRNA-224 to act as biomarkers for HCC diagnosis. Methods:: This study included 50 patients with HCV-induced HCC and 50 patients with HCV-induced liver cirrhosis for comparison as well as 67 healthy volunteers as controls. All participants were subjected to history taking, clinical examination, and laboratory investigations as well as quantification of serum miRNA-96 and miRNA-224 by real-time quantitative PCR. Results:: MicroRNA 224 level was significantly higher in HCC than the other two groups and was significantly higher in liver cirrhosis than the control group. MicroRNA 96 level was higher in HCC than the control group and was higher in cirrhotic group than both HCC and control groups. However, it doesn’t reach the statistical significance level. The best cut-off value of microRNA 96 for detecting HCC was 3.414 with a sensitivity of 67% and a specificity of 67%, (p-value Conclusion:: miRNA-224 could serve as a biomarker for the HCC diagnosis.
- 3 November 2020
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 16, 1-8
Role of MicroRNAs (224 and 96) as Novel Biomarkers for Hepatocellular Carcinoma
Background:: In the early stages of HCC, it is unsatisfactory to depend on alpha-fetoprotein for diagnosis. Objective:: The current study evaluated the possibility of the two miRNAs which are miRNA-96 and miRNA-224 to act as biomarkers for HCC diagnosis. Methods:: This study included 50 patients with HCV-induced HCC and 50 patients with HCV-induced liver cirrhosis for comparison as well as 67 healthy volunteers as controls. All participants were subjected to history taking, clinical examination, and laboratory investigations as well as quantification of serum miRNA-96 and miRNA-224 by real-time quantitative PCR. Results:: MicroRNA 224 level was significantly higher in HCC than the other two groups and was significantly higher in liver cirrhosis than the control group. MicroRNA 96 level was higher in HCC than the control group and was higher in cirrhotic group than both HCC and control groups. However, it doesn’t reach the statistical significance level. The best cut-off value of microRNA 96 for detecting HCC was 3.414 with a sensitivity of 67% and a specificity of 67%, (p-value Conclusion:: miRNA-224 could serve as a biomarker for the HCC diagnosis.